The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis.
HIV
health economics
Journal
BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
04
03
2021
accepted:
24
06
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
7
8
2021
Statut:
ppublish
Résumé
HIV self-testing (HIVST) has been shown to be acceptable, feasible and effective in increasing HIV testing uptake. Novel testing strategies are critical to achieving the UNAIDS target of 95% HIV-positive diagnosis by 2025 in South Africa and globally. We modelled the impact of six HIVST kit distribution modalities (community fixed-point, taxi ranks, workplace, partners of primary healthcare (PHC) antiretroviral therapy (ART) patients), partners of pregnant women, primary PHC distribution) in South Africa over 20 years (2020-2039), using data collected alongside the Self-Testing AfRica Initiative. We modelled two annual distribution scenarios: (A) 1 million HIVST kits (current) or (B) up to 6.7 million kits. Incremental economic costs (2019 US$) were estimated from the provider perspective; assumptions on uptake and screening positivity were based on surveys of a subset of kit recipients and modelled using the Thembisa model. Cost-effectiveness of each distribution modality compared with the status-quo distribution configuration was estimated as cost per life year saved (estimated from life years lost due to AIDS) and optimised using a fractional factorial design. The largest impact resulted from secondary HIVST distribution to partners of ART patients at PHC (life years saved (LYS): 119 000 (scenario A); 393 000 (scenario B)). However, it was one of the least cost-effective modalities (A: $1394/LYS; B: $4162/LYS). Workplace distribution was cost-saving ($52-$76 million) and predicted to have a moderate epidemic impact (A: 40 000 LYS; B: 156 000 LYS). An optimised scale-up to 6.7 million tests would result in an almost threefold increase in LYS compared with a scale-up of status-quo distribution (216 000 vs 75 000 LYS). Optimisation-informed distribution has the potential to vastly improve the impact of HIVST. Using this approach, HIVST can play a key role in improving the long-term health impact of investment in HIVST.
Sections du résumé
BACKGROUND
HIV self-testing (HIVST) has been shown to be acceptable, feasible and effective in increasing HIV testing uptake. Novel testing strategies are critical to achieving the UNAIDS target of 95% HIV-positive diagnosis by 2025 in South Africa and globally.
METHODS
We modelled the impact of six HIVST kit distribution modalities (community fixed-point, taxi ranks, workplace, partners of primary healthcare (PHC) antiretroviral therapy (ART) patients), partners of pregnant women, primary PHC distribution) in South Africa over 20 years (2020-2039), using data collected alongside the Self-Testing AfRica Initiative. We modelled two annual distribution scenarios: (A) 1 million HIVST kits (current) or (B) up to 6.7 million kits. Incremental economic costs (2019 US$) were estimated from the provider perspective; assumptions on uptake and screening positivity were based on surveys of a subset of kit recipients and modelled using the Thembisa model. Cost-effectiveness of each distribution modality compared with the status-quo distribution configuration was estimated as cost per life year saved (estimated from life years lost due to AIDS) and optimised using a fractional factorial design.
RESULTS
The largest impact resulted from secondary HIVST distribution to partners of ART patients at PHC (life years saved (LYS): 119 000 (scenario A); 393 000 (scenario B)). However, it was one of the least cost-effective modalities (A: $1394/LYS; B: $4162/LYS). Workplace distribution was cost-saving ($52-$76 million) and predicted to have a moderate epidemic impact (A: 40 000 LYS; B: 156 000 LYS). An optimised scale-up to 6.7 million tests would result in an almost threefold increase in LYS compared with a scale-up of status-quo distribution (216 000 vs 75 000 LYS).
CONCLUSION
Optimisation-informed distribution has the potential to vastly improve the impact of HIVST. Using this approach, HIVST can play a key role in improving the long-term health impact of investment in HIVST.
Identifiants
pubmed: 34275876
pii: bmjgh-2021-005598
doi: 10.1136/bmjgh-2021-005598
pmc: PMC8287627
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Commentaires et corrections
Type : ErratumIn
Informations de copyright
©World Health Organization 2021. Licensee BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
AIDS. 2020 Nov 15;34(14):2115-2123
pubmed: 32796213
PLoS One. 2019 Feb 26;14(2):e0210497
pubmed: 30807573
Bull World Health Organ. 1994;72(3):429-45
pubmed: 8062401
Sci Rep. 2019 Sep 2;9(1):12621
pubmed: 31477764
BMJ Glob Health. 2021 Jul;6(Suppl 4):
pubmed: 34275874
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25255
pubmed: 30907499
AIDS Behav. 2019 Sep;23(Suppl 2):130-141
pubmed: 31197701
PLoS One. 2018 Mar 13;13(3):e0193858
pubmed: 29534077
J Int AIDS Soc. 2020 Aug;23(8):e25587
pubmed: 32767707
AIDS Care. 2019 Feb;31(2):186-192
pubmed: 30058362
Pan Afr Med J. 2019 Jun 04;33:83
pubmed: 31448045
PLoS One. 2018 Aug 27;13(8):e0202521
pubmed: 30148846
Lancet HIV. 2021 Mar;8(3):e158-e165
pubmed: 33549166
BMJ Glob Health. 2021 Jul;6(Suppl 4):
pubmed: 34275873
PLoS One. 2020 May 14;15(5):e0232883
pubmed: 32407342
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25243
pubmed: 30907498
AIDS. 2015 Jul 17;29(11):1401-9
pubmed: 26091299